Pomalidomide for High Risk Multiple Myeloma

UARK 2010-01, PHASE II TRIAL OF CC-4047 (POMALIDOMIDE) IN HIGH RISK MULTIPLE MYELOMA THAT IS RELAPSING OR REFRACTORY TO PRIOR THERAPY (CELGENE PO-MM-PI-0029)

 

Title: 

UARK 2010-01, PHASE II TRIAL OF CC-4047 (POMALIDOMIDE) IN HIGH RISK MULTIPLE MYELOMA THAT IS RELAPSING OR REFRACTORY TO PRIOR THERAPY (CELGENE PO-MM-PI-0029)

Sponsor: 

UAMS MIRT and Celgene

PI: 

Saad Usmani, MD

Phase: 

II 

Purpose: 

This study is designed to determine the effects of CC-4047 when given to patients with relapsing or refractory multiple myeloma. 

Eligibility:  

Approximately 80 patients, male or female, age 18 or older, regardless of race or ethnicity, will participate in this study which is conducted at UAMS only. You are being asked to take part in this study because you have multiple myeloma which has returned or has not responded to prior therapy.  Additionally, your physician feels that it may be reasonable for you to participate in this study of a new treatment for multiple myeloma. 

Treatment: 

CC-4047 is given as a capsule that you will take in the evening at approximately the same time each day.  You will take daily CC-4047 for 21 days, followed by 7 days of rest.  This 28-day period is one cycle.   You may continue to receive treatment as long as your myeloma does not get worse or you are not having unacceptable side effects for approximately 2 years.  Therefore, a maximum of 26 cycles of pomalidomide may be given as a part of this study.

Contact: 

Nathan Petty
E-mail: pettynathanm@uams.edu
Phone: 501-526-6990 ext. 2435